MCID: GLC036
MIFTS: 51

Glucagonoma

Categories: Endocrine diseases, Gastrointestinal diseases, Rare diseases

Aliases & Classifications for Glucagonoma

MalaCards integrated aliases for Glucagonoma:

Name: Glucagonoma 53 59 55 73
Glucagonoma Syndrome 53 59 29
Weight Loss, Necrolytic Migratory Erythema , Diabetes, Stomatitis, and Diarrhea 53

Characteristics:

Orphanet epidemiological data:

59
glucagonoma
Inheritance: Not applicable; Prevalence: <1/1000000 (Europe); Age of onset: Adult; Age of death: adult;

Classifications:



Summaries for Glucagonoma

MalaCards based summary : Glucagonoma, also known as glucagonoma syndrome, is related to insulinoma and pancreatitis, and has symptoms including diarrhea An important gene associated with Glucagonoma is SST (Somatostatin), and among its related pathways/superpathways are G alpha (s) signalling events and Gastric acid production. The drugs Levoleucovorin and Fluorouracil have been mentioned in the context of this disorder. Affiliated tissues include pancreas, liver and skin, and related phenotypes are depressivity and diabetes mellitus

Wikipedia : 76 A glucagonoma is a rare tumor of the alpha cells of the pancreas that results in the overproduction of... more...

Related Diseases for Glucagonoma

Diseases related to Glucagonoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 100)
# Related Disease Score Top Affiliating Genes
1 insulinoma 30.5 CHGA SCT SST
2 pancreatitis 30.1 SCT SST
3 angiodysplasia 29.9 SCT SST
4 multiple endocrine neoplasia, type i 29.7 CHGA GHRH SCT SST VIP
5 gastrinoma 29.7 CHGA SCT SST VIP
6 somatostatinoma 29.6 CHGA SST VIP
7 vipoma 29.5 CHGA SCT SST VIP
8 neuroendocrine tumor 29.5 CHGA CHGB SST
9 zollinger-ellison syndrome 29.4 CHGA GHRH SCT SST
10 pheochromocytoma 29.1 CHGA CHGB SST VIP
11 pancreatic neuroendocrine tumor 11.4
12 appendiceal l-cell glucagon-like peptide producing tumor 11.1
13 multiple endocrine neoplasia 10.3
14 dermatitis 10.2
15 adenoma of the pancreas 10.1 CHGA SST
16 gastrointestinal neuroendocrine benign tumor 10.1 CHGA SST
17 gastrointestinal neuroendocrine tumor 10.1 CHGA SST
18 gastric neuroendocrine neoplasm 10.1 CHGA SST
19 pituitary carcinoma 10.1 CHGA SST
20 pancreatoblastoma 10.1 CHGA SST
21 pancreatic cystadenoma 10.1 CHGA SST
22 malignant pheochromocytoma 10.1 CHGA SST
23 gastrointestinal system benign neoplasm 10.1 CHGA SST
24 hyperpituitarism 10.1 GHRH SST
25 duodenogastric reflux 10.1 SCT SST
26 dumping syndrome 10.1 SCT SST
27 endocrine organ benign neoplasm 10.1 CHGA SST
28 tsh producing pituitary tumor 10.1 GHRH SST
29 duodenal disease 10.1 SCT SST
30 atrophic gastritis 10.1 CHGA SST
31 steatorrhea 10.1 SCT SST
32 isolated growth hormone deficiency, type ii 10.1 GHRH SST
33 pituitary-dependent cushing's disease 10.1 GHRH SST
34 wdha syndrome 10.1 SST VIP
35 small intestine cancer 10.1 SCT SST
36 merkel cell carcinoma 10.1 CHGA SST
37 postgastrectomy syndrome 10.1 SST VIP
38 pituitary gland disease 10.1 GHRH SST
39 adenoma 10.1
40 paraganglioma 10.1 CHGA SST
41 duodenal ulcer 10.1 SCT SST
42 cryptosporidiosis 10.1 SST VIP
43 pancreas disease 10.1 SCT SST
44 autonomic nervous system benign neoplasm 10.0 CHGA VIP
45 diffuse pulmonary fibrosis 10.0 CHGA VIP
46 hyperprolactinemia 10.0 SST VIP
47 ganglioneuroma 10.0 CHGA VIP
48 acromegaly 10.0 GHRH SST
49 space motion sickness 10.0 SCT VIP
50 acute pancreatitis 10.0 SCT SST

Graphical network of the top 20 diseases related to Glucagonoma:



Diseases related to Glucagonoma

Symptoms & Phenotypes for Glucagonoma

Human phenotypes related to Glucagonoma:

59 32 (show all 43)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 depressivity 59 32 occasional (7.5%) Occasional (29-5%) HP:0000716
2 diabetes mellitus 59 32 frequent (33%) Frequent (79-30%) HP:0000819
3 nausea and vomiting 59 32 frequent (33%) Frequent (79-30%) HP:0002017
4 constipation 59 32 frequent (33%) Frequent (79-30%) HP:0002019
5 hepatomegaly 59 32 frequent (33%) Frequent (79-30%) HP:0002240
6 ascites 59 32 occasional (7.5%) Occasional (29-5%) HP:0001541
7 thromboembolism 59 32 occasional (7.5%) Occasional (29-5%) HP:0001907
8 abnormal blistering of the skin 59 32 frequent (33%) Frequent (79-30%) HP:0008066
9 pruritus 59 32 frequent (33%) Frequent (79-30%) HP:0000989
10 weight loss 59 32 frequent (33%) Frequent (79-30%) HP:0001824
11 increased circulating gonadotropin level 59 32 very rare (1%) Very rare (<4-1%) HP:0000837
12 anorexia 59 32 frequent (33%) Frequent (79-30%) HP:0002039
13 intestinal obstruction 59 32 occasional (7.5%) Occasional (29-5%) HP:0005214
14 chronic fatigue 59 32 frequent (33%) Frequent (79-30%) HP:0012432
15 gastrointestinal hemorrhage 59 32 occasional (7.5%) Occasional (29-5%) HP:0002239
16 extrahepatic cholestasis 59 32 occasional (7.5%) Occasional (29-5%) HP:0012334
17 parathyroid adenoma 59 32 very rare (1%) Very rare (<4-1%) HP:0002897
18 hypercalcemia 59 32 very rare (1%) Very rare (<4-1%) HP:0003072
19 growth hormone excess 59 32 very rare (1%) Very rare (<4-1%) HP:0000845
20 subcutaneous lipoma 59 32 very rare (1%) Very rare (<4-1%) HP:0001031
21 diarrhea 59 32 frequent (33%) Frequent (79-30%) HP:0002014
22 episodic abdominal pain 59 32 frequent (33%) Frequent (79-30%) HP:0002574
23 pituitary adenoma 59 32 very rare (1%) Very rare (<4-1%) HP:0002893
24 adrenocortical adenoma 59 32 very rare (1%) Very rare (<4-1%) HP:0008256
25 skin rash 59 32 frequent (33%) Frequent (79-30%) HP:0000988
26 neoplasm of the pancreas 59 32 hallmark (90%) Very frequent (99-80%) HP:0002894
27 abnormality of the thyroid gland 59 32 very rare (1%) Very rare (<4-1%) HP:0000820
28 glossitis 59 32 frequent (33%) Frequent (79-30%) HP:0000206
29 intrahepatic cholestasis 59 32 occasional (7.5%) Occasional (29-5%) HP:0001406
30 prolactin excess 59 32 very rare (1%) Very rare (<4-1%) HP:0000870
31 steatorrhea 59 32 occasional (7.5%) Occasional (29-5%) HP:0002570
32 acanthocytosis 59 32 frequent (33%) Frequent (79-30%) HP:0001927
33 poor appetite 59 32 frequent (33%) Frequent (79-30%) HP:0004396
34 stomatitis 59 32 frequent (33%) Frequent (79-30%) HP:0010280
35 necrolytic migratory erythema 59 32 frequent (33%) Frequent (79-30%) HP:0031181
36 primary hyperparathyroidism 59 32 very rare (1%) Very rare (<4-1%) HP:0008200
37 normochromic anemia 59 32 frequent (33%) Frequent (79-30%) HP:0001895
38 intermittent jaundice 59 32 occasional (7.5%) Occasional (29-5%) HP:0001046
39 lack of bowel sounds 59 32 occasional (7.5%) Occasional (29-5%) HP:0030145
40 abnormal gastrointestinal motility 59 32 occasional (7.5%) Occasional (29-5%) HP:0030895
41 hypercortisolism 59 Very rare (<4-1%)
42 increased circulating cortisol level 32 very rare (1%) HP:0003118
43 abnormality of the abdomen 59 Occasional (29-5%)

UMLS symptoms related to Glucagonoma:


diarrhea

Drugs & Therapeutics for Glucagonoma

Drugs for Glucagonoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 104)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Levoleucovorin Approved, Investigational Phase 2, Phase 3,Phase 1 68538-85-2
2
Fluorouracil Approved Phase 2, Phase 3 51-21-8 3385
3
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3
4
leucovorin Approved Phase 2, Phase 3,Phase 3,Phase 1 58-05-9 6006 143
5
Oxaliplatin Approved, Investigational Phase 2, Phase 3,Phase 1 61825-94-3 43805 6857599 5310940 9887054
6
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
7
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
8 Pancreatic Polypeptide Investigational Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 59763-91-6
9 Angiogenesis Inhibitors Phase 2, Phase 3,Phase 1
10 Vitamin B9 Phase 2, Phase 3
11 Immunologic Factors Phase 2, Phase 3,Phase 1
12 Immunosuppressive Agents Phase 2, Phase 3,Phase 1
13 Angiogenesis Modulating Agents Phase 2, Phase 3,Phase 1
14 Folate Phase 2, Phase 3
15 Antimetabolites, Antineoplastic Phase 2, Phase 3,Phase 1
16 Antimetabolites Phase 2, Phase 3,Phase 1
17 Liver Extracts Phase 3,Phase 2,Phase 1,Not Applicable
18 Cola Phase 3,Phase 2,Phase 1
19 Central Nervous System Depressants Phase 3
20 Adjuvants, Anesthesia Phase 3
21 Anesthetics, Intravenous Phase 3
22 Analgesics, Opioid Phase 3
23 Peripheral Nervous System Agents Phase 3
24 Anesthetics, General Phase 3
25 Analgesics Phase 3
26 Narcotics Phase 3
27 Anesthetics Phase 3
28
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1 22916-47-8 4189
29
Sirolimus Approved, Investigational Phase 2,Phase 1 53123-88-9 46835353 6436030 5284616
30
Everolimus Approved Phase 2,Phase 1 159351-69-6 6442177
31
Nicotinamide Approved, Investigational Phase 2 98-92-0 936
32
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
33
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
34
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
35
Capecitabine Approved, Investigational Phase 2,Phase 1 154361-50-9 60953
36
Streptozocin Approved, Investigational Phase 2 18883-66-4 29327
37
Cisplatin Approved Phase 2 15663-27-1 2767 441203 84093
38
Octreotide Approved, Investigational Phase 2,Phase 1 83150-76-9 383414 6400441
39
Irinotecan Approved, Investigational Phase 2 100286-90-6, 97682-44-5 60838
40
Pancrelipase Approved, Investigational Phase 2,Phase 1 53608-75-6
41
Melphalan Approved Phase 2 148-82-3 4053 460612
42
Somatostatin Approved, Investigational Phase 2,Phase 1 51110-01-1, 38916-34-6 53481605
43
Dacarbazine Approved, Investigational Phase 2,Phase 1 4342-03-4 5351166
44
Temozolomide Approved, Investigational Phase 2,Phase 1 85622-93-1 5394
45
Pasireotide Approved Phase 2 396091-73-9 9941444
46
Romidepsin Approved, Investigational Phase 2 128517-07-7 5352062
47
Gemcitabine Approved Phase 2 95058-81-4 60750
48
Panobinostat Approved, Investigational Phase 2 404950-80-7 6918837
49
Niacin Approved, Investigational, Nutraceutical Phase 2 59-67-6 938
50
Vitamin A Approved, Nutraceutical, Vet_approved Phase 2 11103-57-4, 68-26-8 445354

Interventional clinical trials:

(show all 36)
# Name Status NCT ID Phase Drugs
1 Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors Unknown status NCT00227617 Phase 2, Phase 3 5-fluorouracil;leucovorin;oxaliplatin
2 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
3 Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer Completed NCT01010126 Phase 2 Temsirolimus
4 Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors Completed NCT00131911 Phase 2 sorafenib tosylate
5 Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors Completed NCT00075439 Phase 2 gefitinib
6 Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer Completed NCT00454363 Phase 2 Pazopanib Hydrochloride
7 PS-341 in Treating Patients With Metastatic Neuroendocrine Tumors Completed NCT00017199 Phase 2 bortezomib
8 Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors Completed NCT00602082 Phase 2 capecitabine;cisplatin;streptozocin
9 AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors Completed NCT00427349 Phase 2 AMG 706;octreotide
10 Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery Completed NCT00416767 Phase 2 fluorouracil;irinotecan hydrochloride;leucovorin calcium
11 Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer Completed NCT00096083 Phase 2 isolated perfusion;melphalan
12 Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors Completed NCT00027638 Phase 2 thalidomide
13 Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors Active, not recruiting NCT02259725 Phase 2 regorafenib
14 Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors Active, not recruiting NCT01824875 Phase 2 temozolomide;capecitabine
15 Capecitabine, Temozolomide and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors Active, not recruiting NCT01525082 Phase 2 capecitabine;temozolomide
16 Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin Terminated NCT00958841 Phase 2 pasireotide LAR
17 Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery Terminated NCT02031536 Phase 2 everolimus
18 Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer Terminated NCT02273752 Phase 2 Everolimus
19 Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors Terminated NCT00084461 Phase 2 romidepsin
20 Panobinostat & Bortezomib in Pancreatic Cancer Progressing on Gemcitabine Therapy Terminated NCT01056601 Phase 2 Bortezomib;Panobinostat
21 Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors Terminated NCT00466856 Phase 2 octreotide acetate
22 Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors Withdrawn NCT02108782 Phase 2 dovitinib lactate
23 Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors Withdrawn NCT00227773 Phase 2 octreotide acetate;vatalanib
24 Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors Completed NCT00655655 Phase 1 everolimus;vatalanib
25 Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu Completed NCT00004074 Phase 1
26 Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma Completed NCT01204476 Phase 1 Everolimus;Octreotide Acetate
27 Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer Completed NCT00005842 Phase 1 tipifarnib
28 Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer Completed NCT00006368 Phase 1
29 Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum Completed NCT00005860 Phase 1 floxuridine;leucovorin calcium;oxaliplatin
30 Laser Tissue Welding - Distal Pancreatectomy Sealing Study Recruiting NCT03147768 Phase 1
31 Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer Terminated NCT00002947 Phase 1
32 Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor Withdrawn NCT02831179 Phase 1 Capecitabine;Temozolomide;Veliparib
33 Disease-Specific Questionnaire in Assessing Quality of Life in Patients With Gastrointestinal-Related Neuroendocrine Tumors Unknown status NCT00454376
34 DOTATOC PET/CT for Imaging NET Patients Recruiting NCT03583528
35 Gastroenteral-Pancreatic Neuroendocrine Tumors in Taiwan Enrolling by invitation NCT02102893
36 Doxorubicin Beads in Treating Patients With Unresectable Liver Metastases From Neuroendocrine Tumors Terminated NCT00730483 Not Applicable PVA microporous hydrospheres/doxorubicin hydrochloride

Search NIH Clinical Center for Glucagonoma

Genetic Tests for Glucagonoma

Genetic tests related to Glucagonoma:

# Genetic test Affiliating Genes
1 Glucagonoma Syndrome 29

Anatomical Context for Glucagonoma

MalaCards organs/tissues related to Glucagonoma:

41
Pancreas, Liver, Skin, Bone, Pituitary, Thyroid, Small Intestine

Publications for Glucagonoma

Articles related to Glucagonoma:

(show top 50) (show all 313)
# Title Authors Year
1
A Case Series of Molecular Imaging of Glucagonoma After Initial Therapy-68Ga-DOTATATE PET/CT Reveals Similar Results as in Neuroendocrine Tumors of Other Origin in Follow-up and Re-evaluation. ( 29432346 )
2018
2
A review of cutaneous manifestations within glucagonoma syndrome: necrolytic migratory erythema. ( 29450880 )
2018
3
Glucagonoma and the glucagonoma syndrome. ( 29435000 )
2018
4
Normoglycemic glucagonoma syndrome associated with necrolytic migratory erythema. ( 29419911 )
2018
5
Glucagonoma With Necrolytic Migratory Erythema: Metabolic Profile and Detection of Biallelic Inactivation of DAXX Gene. ( 29688432 )
2018
6
Erythema as a Visual Surrogate Marker of Glucagonoma. ( 29526932 )
2018
7
Glucagonoma-Associated Necrolytic Migratory Erythema: The Broad Spectrum of the Clinical and Histopathological Findings and Clues to the Diagnosis. ( 30124507 )
2018
8
Necrolytic migratory erythema associated with glucagonoma treated successfully with cyclosporine. ( 28508546 )
2017
9
Glucagonoma-Associated Rash. ( 28273025 )
2017
10
Psoriasiform lesions: Uncommon presentation of glucagonoma. ( 29074313 )
2017
11
Emergency pancreatic resection for glucagonoma associated with severe necrolytic migratory erythema. ( 28982222 )
2017
12
Necrolytic migratory erythema: A diagnostic clue in glucagonoma syndrome. ( 27567335 )
2017
13
Glucagonoma syndrome with serous oligocystic adenoma: A rare case report. ( 29069049 )
2017
14
Malignant transformation of glucagonoma with SPECT/CT In-111 OctreoScan features: A case report. ( 29390362 )
2017
15
Glucagonoma syndrome: report of one case. ( 28138636 )
2016
16
Glucagonoma and Glucagonoma Syndrome: A Case Report with Review of Recent Advances in Management. ( 26981306 )
2016
17
Paediatric necrolytic migratory erythema as a presenting sign of glucagonoma syndrome. ( 26585841 )
2016
18
Necrolytic migratory erythema and pancreatic glucagonoma. ( 27622478 )
2016
19
Glucagonoma syndrome: a review and update on treatment. ( 27422767 )
2016
20
Paradoxical presentation of glucagonoma with delayed onset of necrolytic migratory erythema. ( 25448171 )
2015
21
A Novel Missense Mutation of the MEN1 Gene in a Patient with Multiple Endocrine Neoplasia Type 1 with Glucagonoma and Obesity. ( 26424307 )
2015
22
Glucagon receptor gene mutations with hyperglucagonemia but without the glucagonoma syndrome. ( 25914784 )
2015
23
Delayed diagnosis of glucagonoma syndrome: a case report. ( 26679842 )
2015
24
Glucagonoma syndrome: A case report. ( 26622635 )
2015
25
Imaging features of glucagonoma syndrome: A case report and review of the literature. ( 25789004 )
2015
26
Glucagonoma syndrome associated with necrolytic migratory erythema. ( 26248239 )
2015
27
Reversal of dilated cardiomyopathy after glucagonoma excision. ( 25553769 )
2015
28
Proposed Radiation Induced Hormone Crisis in a Patient with Glucagonoma. ( 26493062 )
2015
29
Glucagonoma Pancreatic Neuroendocrine Tumor Treated With 177Lu DOTATATE Induction and Maintenance Peptide Receptor Radionuclide Therapy. ( 26204206 )
2015
30
Glucagonoma-induced acute heart failure. ( 25520848 )
2014
31
Rapid improvement of glucagonoma-related necrolytic migratory erythema with octreotide. ( 26183746 )
2014
32
Novel mutation 928G&amp;gt;C of MEN1 gene in a familial multiple endocrine neoplasia type 1 case (MEN1) with co-existence of insulinoma and glucagonoma. ( 25047095 )
2014
33
Glucagonoma syndrome: a case report with focus on skin disorders. ( 25152626 )
2014
34
Non-secreting benign glucagonoma diagnosed incidentally in a patient with refractory thrombocytopenic thrombotic purpura: report of a case. ( 25373364 )
2014
35
Glucagonoma with necrolytic migratory erythema exhibiting responsiveness to subcutaneous octreotide injections. ( 23389434 )
2013
36
Pancreatic glucagonoma metastasising to the right ovary five years after initial surgery: a case report. ( 24018597 )
2013
37
Enhanced glucagon-like peptide-1 secretion in a patient with glucagonoma: implications for glucagon-like peptide-1 secretion from pancreatic I+ cells in vivo. ( 24008099 )
2013
38
Pancreatic glucagonoma with pancreatic calcification. ( 23719610 )
2013
39
Necrolytic migratory erythema and glucagonoma rising from pancreatic head. ( 23890147 )
2013
40
Putting the pieces together: necrolytic migratory erythema and the glucagonoma syndrome. ( 23681843 )
2013
41
Hypercalcemia appeared in a patient with glucagonoma treated with octreotide acetate long-acting release. ( 23062642 )
2012
42
Is necrolytic migratory erythema due to glucagonoma a misnomer? A more apt name might be mucosal and intertriginous erosive dermatitis. ( 22513058 )
2012
43
Necrolytic migratory erythema as the first manifestation of glucagonoma. ( 22970401 )
2012
44
Functioning glucagonoma associated with primary hyperparathyroidism: multiple endocrine neoplasia type 1 or incidental association? ( 23259638 )
2012
45
An unusual case of subclinical diffuse glucagonoma coexisting with two nodules in the pancreas: characteristic features on computed tomography. ( 22239827 )
2012
46
Necrolytic migratory erythema associated with glucagonoma syndrome diagnosed by (68) Ga-DOTANOC PET-CT. ( 23279825 )
2012
47
Bone lesions in recurrent glucagonoma: A case report and review of literature. ( 22737277 )
2012
48
Glucagon cell adenomatosis: a new entity associated with necrolytic migratory erythema and glucagonoma syndrome. ( 21763589 )
2011
49
Glucagonoma syndrome: a case report. ( 21859461 )
2011
50
Diabetes Cured by Pancreaticoduodenectomy: A Case Report of Glucagonoma Masquerading as Carcinoma of the Head of Pancreas. ( 22086709 )
2011

Variations for Glucagonoma

Expression for Glucagonoma

Search GEO for disease gene expression data for Glucagonoma.

Pathways for Glucagonoma

Pathways related to Glucagonoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.3 GHRH SCT VIP
2 9.47 SCT VIP

GO Terms for Glucagonoma

Cellular components related to Glucagonoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.35 CHGA CHGB GHRH SCT SST
2 perikaryon GO:0043204 9.26 GHRH VIP
3 secretory granule GO:0030141 9.16 CHGA CHGB
4 extracellular region GO:0005576 9.1 CHGA CHGB GHRH SCT SST VIP

Biological processes related to Glucagonoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor signaling pathway GO:0007186 9.26 GHRH SCT SST VIP
2 adenylate cyclase-activating G protein-coupled receptor signaling pathway GO:0007189 9.16 GHRH VIP
3 regulation of signaling receptor activity GO:0010469 9.02 CHGB GHRH SCT SST VIP

Molecular functions related to Glucagonoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neuropeptide hormone activity GO:0005184 9.16 GHRH VIP
2 hormone activity GO:0005179 9.02 CHGB GHRH SCT SST VIP
3 peptide hormone receptor binding GO:0051428 8.96 GHRH VIP

Sources for Glucagonoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....